Revvity Inc. stock faces pressure amid life sciences slowdown and acquisition integration challenges

Revvity Inc. (ISIN: US76155R1086) reports mixed Q4 results, with revenue growth stalling in key diagnostics segments. Shares on NYSE dipped as investors weigh ongoing integration risks from recent deals. DACH investors should watch for exposure to European healthtech demand amid regulatory shifts.

Revvity Inc., a leader in health sciences solutions, released its fourth-quarter and full-year 2025 results on February 25, 2026. The company posted revenue of $815 million for Q4, up 1% organically from the prior year but missing analyst expectations slightly. This slowdown in its life sciences and diagnostics businesses triggered a sell-off in the Revvity Inc. stock on the NYSE in US dollars, dropping over 8% in the immediate aftermath to around $105 USD per share.

As of: 22.03.2026

By Dr. Elena Voss, Senior Life Sciences Analyst – Revvity's pivot to precision medicine tools positions it well for long-term growth, but near-term execution in a cautious market demands vigilance from European investors.

Core Business Breakdown and Q4 Highlights

Revvity operates through two main segments: Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical, which includes tools for drug discovery and research, drove most of the growth with 5% organic increase. Diagnostics, however, saw a flat performance amid softer demand for clinical testing reagents.

The company's adjusted EPS came in at $1.15 for the quarter, beating estimates by 3 cents. Full-year revenue reached $2.75 billion, reflecting steady progress post its 2023 rebranding from PerkinElmer. Management highlighted strength in genomics and imaging products, key for AI-driven drug development.

Yet, the market fixated on guidance. Revvity forecasts 2026 revenue growth of 2-4% organically, below consensus of 5%. This conservative outlook stems from persistent macro headwinds in academic funding and biotech spending. On the NYSE, the Revvity Inc. stock has traded in a range of $100-120 USD over the past three months, reflecting these uncertainties.

CEO Prahlad Singh emphasized operational discipline, with adjusted operating margins expanding to 28%. Free cash flow hit $450 million for the year, supporting $200 million in share repurchases. Investors appreciate this capital return amid tepid growth.

Acquisition Integration: Progress and Pitfalls

Revvity's transformation accelerated with the $2.45 billion acquisition of BioLegend in 2023, bolstering its reagents portfolio. Integration remains a focal point. The company reported $150 million in synergies realized to date, on track for $200 million annual run-rate by year-end 2026.

Challenges persist in harmonizing IT systems and sales channels. Q4 saw minor disruptions in supply chain for certain antibodies, contributing to the diagnostics miss. Management now targets full integration by mid-2026, unlocking cross-selling opportunities in Europe and Asia.

For DACH investors, this matters as Revvity expands its footprint in Germany via BioLegend's tech. The region accounts for 15% of EMEA sales, with growth in proteomics tools for pharma giants like Bayer and Roche.

Market Reaction and Valuation Snapshot

The Revvity Inc. stock fell sharply post-earnings, closing at $102.50 USD on the NYSE on February 26, 2026, down 9.2% for the day. Volume spiked to 3.2 million shares, double the average. Analysts trimmed targets, with JPMorgan cutting to $125 USD from $135 USD, maintaining overweight.

At current levels, Revvity trades at 18x forward earnings, a discount to peers like Thermo Fisher at 25x. EV/EBITDA stands at 12x, attractive for a firm with 20% ROIC. Dividend yield of 0.4% is modest, but buybacks provide support.

Short interest rose to 4.5% of float, signaling skepticism on growth delivery. Options flow showed put buying, with March $100 strikes in demand.

Risks and Headwinds in Life Sciences

Sector tailwinds from AI in drug discovery contrast with near-term risks. Biotech funding remains constrained, with VC investment down 20% YoY per PitchBook data. Revvity's 40% exposure to academic and government clients heightens vulnerability.

Regulatory hurdles loom in diagnostics, particularly FDA scrutiny on companion diagnostics. Supply chain fragility for rare reagents persists post-pandemic. Competition intensifies from Danaher and Agilent in high-throughput screening.

Currency swings impact DACH sales, as 25% of revenue is international. A stronger euro could erode margins on exports to the US.

Why DACH Investors Should Pay Attention

German-speaking investors hold significant stakes in life sciences via funds like DWS and Union Investment. Revvity's tools support key DACH pharma players, including partnerships with Siemens Healthineers for imaging workflows.

Europe's €95 billion Horizon Europe program boosts demand for Revvity's sequencing solutions. Switzerland's biotech cluster in Basel offers upside, with Revvity supplying 10% of reagents to Novartis projects. Austria's medtech growth aligns with diagnostics strength.

Tax-efficient US exposure via NYSE appeals to DACH portfolios seeking diversification beyond STOXX Europe 600. At 18x earnings, it offers value amid regional valuations at 14x.

Strategic Catalysts Ahead

Revvity eyes bolt-on M&A with $1 billion dry powder. Pipeline includes AI-enhanced data analysis software, launching Q2 2026. Partnerships with hyperscalers like AWS could accelerate adoption.

Sustainability initiatives target net-zero by 2040, appealing to ESG-focused DACH funds. Margin expansion from automation should drive EPS growth to 10% CAGR through 2028.

Analyst consensus points to $130 USD target on NYSE, implying 25% upside. Buy ratings dominate at 70% of coverage.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.